Literature DB >> 14519432

Upregulation of GLUT1 expression is necessary for hypertrophy and survival of neonatal rat cardiomyocytes.

Michael R Morissette1, Amy L Howes, Tong Zhang, Joan Heller Brown.   

Abstract

During hypertrophy the heart increases its utilization of glucose and decreases that of fatty acids, resuming a fetal pattern of substrate metabolism. As demonstrated here, GLUT1 protein expression is increased in association with in vivo pressure-overload-induced hypertrophy. The relationship of changes in GLUT1 to enhanced glucose uptake and to cardiomyocyte hypertrophy and survival is not known. To explore this question we first examined the effect of prostaglandin F2alpha (PGF2alpha), an established hypertrophic agonist, on GLUT1 expression and glucose uptake in neonatal rat ventricular myocytes (NRVMs). PGF2alpha treatment for 24 h led to a fivefold increase in GLUT1 expression and a sixfold increase in glucose uptake. However, NRVMs cultured in the absence of glucose or with 3-O-methyl glucose, a competitive inhibitor of glucose uptake, still exhibited PGF2alpha-induced hypertrophic growth. In addition, we determined that overexpression of GLUT1 using adenovirus was insufficient to cause an increase in cell size, myofibrillar organization, or atrial natriuretic factor (ANF) expression. On the other hand, adenoviral overexpression of antisense GLUT1 (which blocked PGF2alpha-induced increases in GLUT1 protein) prevented PGF2alpha-stimulated cell enlargement and increases in ANF transcription. Overexpression of GLUT1 or addition of PGF2alpha also protected cells against serum deprivation-induced apoptosis; this effect was blocked by antisense GLUT1 but, surprisingly, was not dependent on glucose. Together, these data suggest that upregulation of GLUT1 serves a role in agonist-induced hypertrophy and survival which can be dissociated from its role in glucose transport.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519432     DOI: 10.1016/s0022-2828(03)00212-8

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  17 in total

Review 1.  Glucose transporters in diabetic nephropathy.

Authors:  Frank C Brosius; Charles W Heilig
Journal:  Pediatr Nephrol       Date:  2005-02-17       Impact factor: 3.714

2.  Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1.

Authors:  Yuxing Zhao; Brian J Altman; Jonathan L Coloff; Catherine E Herman; Sarah R Jacobs; Heather L Wieman; Jessica A Wofford; Leah N Dimascio; Olga Ilkayeva; Ameeta Kelekar; Tannishtha Reya; Jeffrey C Rathmell
Journal:  Mol Cell Biol       Date:  2007-03-19       Impact factor: 4.272

Review 3.  Cell metabolism: an essential link between cell growth and apoptosis.

Authors:  Emily F Mason; Jeffrey C Rathmell
Journal:  Biochim Biophys Acta       Date:  2010-09-08

4.  A systems genetics approach identifies Trp53inp2 as a link between cardiomyocyte glucose utilization and hypertrophic response.

Authors:  Marcus M Seldin; Eric D Kim; Milagros C Romay; Shen Li; Christoph D Rau; Jessica J Wang; Karthickeyan Chella Krishnan; Yibin Wang; Arjun Deb; Aldons J Lusis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-02-24       Impact factor: 4.733

5.  GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure.

Authors:  Renata O Pereira; Adam R Wende; Curtis Olsen; Jamie Soto; Tenley Rawlings; Yi Zhu; Christian Riehle; E Dale Abel
Journal:  J Mol Cell Cardiol       Date:  2014-02-25       Impact factor: 5.000

Review 6.  Eicosanoid signalling pathways in the heart.

Authors:  Christopher M Jenkins; Ari Cedars; Richard W Gross
Journal:  Cardiovasc Res       Date:  2008-12-14       Impact factor: 10.787

7.  Mechanisms and methods in glucose metabolism and cell death.

Authors:  Yuxing Zhao; Heather L Wieman; Sarah R Jacobs; Jeffrey C Rathmell
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

8.  Leukaemia inhibitory factor stimulates glucose transport in isolated cardiomyocytes and induces insulin resistance after chronic exposure.

Authors:  G Florholmen; G H Thoresen; A C Rustan; J Jensen; G Christensen; V Aas
Journal:  Diabetologia       Date:  2006-02-18       Impact factor: 10.122

Review 9.  Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy.

Authors:  N Fillmore; J Mori; G D Lopaschuk
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

10.  Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.

Authors:  Arpita Kalla Vyas; Kai-Chien Yang; Dennis Woo; Anatoly Tzekov; Attila Kovacs; Patrick Y Jay; Paul W Hruz
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.